{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=93", "query": { "condition": "Advanced Malignancy", "page": 93 }, "page_size": 10 }, "pagination": { "page": 93, "page_size": 10, "total_count": 9820, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=94&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=92&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T01:48:01.618Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02359851", "title": "Pembrolizumab in Treating Patients With Advanced Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIA Uveal Melanoma", "Stage IIIB Uveal Melanoma", "Stage IIIC Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-05", "completion_date": "2019-08-27", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 2, "location_summary": "Chicago, Illinois • Nashville, Tennessee", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359851" }, { "nct_id": "NCT00364351", "title": "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Vandetanib", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1574, "start_date": "2006-08", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2018-01-25", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 29, "location_summary": "Berkeley, California • Los Angeles, California • Santa Rosa, California + 26 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00364351" }, { "nct_id": "NCT03428802", "title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Locally Advanced Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "POLD1 Gene Mutation", "POLE Gene Mutation", "Recurrent Malignant Solid Neoplasm", "Recurrent Ovarian Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v8", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-03-08", "completion_date": "2027-09-21", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • New York, New York", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428802" }, { "nct_id": "NCT00002828", "title": "Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "raltitrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1995-04", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002828" }, { "nct_id": "NCT00863746", "title": "A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma", "Non-Small-Cell Lung" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 703, "start_date": "2009-04", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2015-01-19", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 3, "location_summary": "Fayetteville, Arkansas • Stanford, California • Philadelphia, Pennsylvania", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863746" }, { "nct_id": "NCT02439346", "title": "Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medical Oncology" ], "interventions": [ { "name": "BAY1143269 tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2015-06-15", "completion_date": "2017-04-24", "has_results": false, "last_update_posted_date": "2018-03-07", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 3, "location_summary": "Dallas, Texas • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02439346" }, { "nct_id": "NCT00631527", "title": "Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Leuprolide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Casodex", "type": "DRUG" }, { "name": "Radiation Therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2008-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-01-29", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00631527" }, { "nct_id": "NCT00034827", "title": "A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Breast Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Pancreatic Neoplasms" ], "interventions": [ { "name": "CI-1040", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2002-01", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2007-05-04", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Blendora, California • Glendale, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Blendora", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00034827" }, { "nct_id": "NCT05937269", "title": "Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphedema of Face", "Head and Neck Cancer" ], "interventions": [ { "name": "Near-infrared fluorescence lymphatic imaging", "type": "COMBINATION_PRODUCT" }, { "name": "advanced pneumatic compression therapy", "type": "DEVICE" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DEVICE" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2023-10-12", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05937269" }, { "nct_id": "NCT00140556", "title": "Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Head and Neck Cancer", "Pharynx Cancer" ], "interventions": [ { "name": "Chemoradiotherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "David M. Brizel, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2005-08", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-11-11T01:48:01.618Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00140556" } ] }